RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
$MRK $BMY:
What Happened in the Stock Market Today:
https://t.co/G0RaqxLyCz
Everything lung cancer! $MRK $BMY #AACR18 https://t.co/evJoPR7Jax
RT @theflynews: On The Fly: Top stock stories for Monday $AMZN $CVS $WBA $ABC $MCK $CAH $TSLA $NFLX $BAC $WPP $ERI $TPCA $NAV $VLKAY $ACIA…
Mad Money Lighting Round @jimcramer https://t.co/92gBWvX6Cn $SPOT $ALKS $JNJ $GERN $ILMN $TMO $AKS $SRNE $MITK $NVDA $KKR $FRPT $ABBV $MRK
RT @JohnCendpts: $BMY not getting much love today -- $MRK in a TKO as analysts score the match.
https://t.co/JHlLY14xxm
RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
#estate assets watch - heaviest volume today: $BAC $GE $BMY $WFC $MU $YNDX $AMD $OCLR $MRK $F $AAPL $RIG $T $CVS… https://t.co/d5eAO7Xvcl
@bradloncar @sharkbiotech so, per Bristol, $BMY's, $MRK's and like PD1s are not really differentiated in terms of clinical effect?
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
Bristol-Myers' Opdivo/Yervoy combo beats chemo in first-line lung cancer; shares down 5% on Merck Keytr... https://t.co/Ha37ljKTEs $BMY $MRK
"There is no question this is a watershed period in the treatment of lung cancer" https://t.co/KQC6A8OUmo $MRK $BMY
RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
More Call Activity $FEYE $OSTK $COP $BABA $KHC $OMC $SCHW $NFLX $KNX $EDU $IVC $MRK $ENDP $FCAU $EPD $VLO $PBR $SPHS $NKTR $CTG $BX $WRD
Big Call Activity https://t.co/B6IlNKq3kX $SCHW $NFLX $KNX $EDU $IVC $MRK $ENDP $FCAU $EPD $VLO $PBR $SPHS $NKTR $CTG $BX $WRD $ICE $JBHT
RT @tradejas: $MRK Immunotherapy scores big win against lung cancer in study https://t.co/FZaIcaVB2M
Biotech Updates 04/16:
$BMY $MRK lung data
$CLDX fail -65%
FDA accepts $ALKS NDA
$APRI -35% more trials required… https://t.co/tTP5zWxTmz
RT @bydavidcrow: The story of Bristol vs Merck in one picture $BMY $MRK https://t.co/smszuY6F94
Part of our strategy includes collaborating with partners to explore new approaches and therapy combinations that c… https://t.co/dnO74dVA7B
RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
RT @JohnCendpts: Tim Anderson on $MRK/$BMY brawl:
$BMY had some decent numbers for one segment, $MRK did well for all. Bottom line: Keytrud…
Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing!… https://t.co/YlRaOHgDJf
RT @AndyBiotech: Novel sexy I/O players now have a mountain to climb vs $MRK chemo combo in lung cancer, plus Alimta going generic by 2022…
We calculated 63-day Expected Return of $MRK for you: 0.6% https://t.co/y7B8KCv7tv
$ONCS $MRK Keytruda + Oncosec ep-IL12 in lung cancer would be nice sometime in the future. https://t.co/KrCQti9har
Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of a… https://t.co/2UUIKhYKrc
RT @MaxJacobsEdison: Maybe $MRK should rename their Pembro trials from KEYNOTE to PLENARY.
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @megtirrell: $MRK data out; Keytruda reduced risk of death in trial by 51% https://t.co/YCSM062iia
RT @drug_czar: Staggering data from $MRK. OS benefit seen in Intent-to-treat of 0.49 and also all patient subgroups including 0.59 HR in no…
RT @JohnCendpts: Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison
$MRK +3%
$BMY…
Merck $MRK came out of its corner swinging Sunday morning, taking a few direct jabs at the defending champion in ch… https://t.co/Ku4zE4O9Dg
$MRK $BMY The Merck vs. Bristol Myers battle isn't over yet, but Merck won today. https://t.co/IHeFBCQ88T
RT @JohnCendpts: #AACR18 brawl. $MRK data: Keytruda/chemo reduces risk of death by 51% -- in high PD-L1 58%. HR of 0.49.
https://t.co/4Kpcx…
RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
Why Merck Is Betting Big on One Cancer Drug
Global sales of more than $3.8 billion for Keytruda in 2017 spur effor… https://t.co/NArrmtoPcv
RT @megtirrell: $MRK data out; Keytruda reduced risk of death in trial by 51% https://t.co/YCSM062iia
$MRK Immunotherapy scores big win against lung cancer in study https://t.co/FZaIcaVB2M
RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
$IMMP $MRK https://t.co/C7KqFIvqUB
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18 https://t.co/hg3CNxxgeF #investing #…
$MRK nice options flow..i see 1 put on the whole list https://t.co/b8X2eLt80N
Shares of Bristol-Myers Squibb fell after its drug was surpassed by Keytruda’s performance.… https://t.co/0lgRNkSl3z
RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
@drug_czar $MRK has a history of deceptive practices. You can't trust them. Here's one of many examples. https://t.co/4qEQahWIuy
$MRK regardless if you have a position or not, you have to truly appreciate what they have done with Keytruda. Amazing accomplishment @Merck
RT @JohnCendpts: #AACR18 brawl. $MRK data: Keytruda/chemo reduces risk of death by 51% -- in high PD-L1 58%. HR of 0.49.
https://t.co/4Kpcx…
RT @theflynews: On The Fly: Top stock stories for Monday $AMZN $CVS $WBA $ABC $MCK $CAH $TSLA $NFLX $BAC $WPP $ERI $TPCA $NAV $VLKAY $ACIA…
#estate asset watch - price / volume leaders today: $BAC $GE $BMY $WFC $MU $AMD $YNDX $OCLR $MRK $AAPL $F $T $RIG… https://t.co/V6HHzetULl
Dow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ https://t.co/DKVRp58o9M #stockmarket #stocks #trading #DowJones
Dow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ https://t.co/tE01Lw1rzM #stockmarket #stocks #trading #DowJones
RT @JohnCendpts: #2
Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison
$MRK $BMY…
RT @JohnCendpts: #3
#AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda
$MRK $BMY
https:/…
@Sanctuary_Bio The difference is $MRK has good revenue growth and will just grow faster with the 1L chemo+Keytruda… https://t.co/6AOeZv166q
RT @JohnCendpts: $BMY not getting much love today -- $MRK in a TKO as analysts score the match.
https://t.co/JHlLY14xxm
RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
RT @matthewherper: My story on the $mrk $bmy data. Short version: $mrk wins again, despite strong $bmy results. https://t.co/0phBvFJd5m
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
RT @JacobPlieth: Probably the most positive slide for $BMY in CM-227, via M Hellmann #AACR18 $MRK $RHHBY https://t.co/jWPi8Qx3ll
RT @crusadernz: Biotech Updates 04/16:
$BMY $MRK lung data
$CLDX fail -65%
FDA accepts $ALKS NDA
$APRI -35% more trials required
$CLVS -10…
RT @JacobPlieth: Justin Gainor (Impower-150 discussant) compares KN-189 vs IMP-150. We LOVE cross-trial comparisons, right? $MRK $RHHBY $BM…
RT @crusadernz: Biotech Updates 04/16:
$BMY $MRK lung data
$CLDX fail -65%
FDA accepts $ALKS NDA
$APRI -35% more trials required
$CLVS -10…
RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new… https://t.co/MBzG3oWQC5
RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
RT @Merck: Don't miss important new data from our #LungCancer study being presented today at #AACR18. Learn more here: https://t.co/DRFdeti…
“This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremel… https://t.co/F59gQJw4oO
RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
In KEYNOTE-054, adjuvant treatment with $MRK's Keytruda of Stage 3 melanoma reduced the risk of disease recurrence… https://t.co/vLRcder2Od
This is a stunning…Keytruda and Optiva are game-changers for lung (and probably other) cancer, and home-runs for… https://t.co/bMPJ6sosUk
Slides from $MRK AACR investor webcast:
https://t.co/FuG1GWrg5c
$LPTX Reveals findings from study testing DKN-01 + $MRK 's KEYTRUDA in patients with advanced esophagogastric cancer https://t.co/k3lwjC7qkG
$LPTX Reveals findings from study testing DKN-01 + $MRK 's KEYTRUDA in patients with advanced esophagogastric cance… https://t.co/4vbceutrCV
RT @Merck: Don't miss important new data from our #LungCancer study being presented today at #AACR18. Learn more here: https://t.co/DRFdeti…
One has to wonder how Nivo/Chemo compares with Pembro/Chemo. I suspect in CM-227 Part 1b, Nivo/chemo was no better… https://t.co/miAz9fXKE3
Nothing was said about Part 1b, which compares nivo/ipi, Nivo/Chemo, and Chemo alone in PDL-1 - patients. This part… https://t.co/3sgN4jrMc5
@megtirell Impressive results for $MRK & $BMY in the battle against lung cancer. https://t.co/cEaDKvvZij
RT @IBD_AGatlin: Can this smaller biotech actually rival Merck, Bristol in cancer drugs? $TSRO $MRK $BMY https://t.co/4XMvQlXf5t
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
RT @crusadernz: Biotech Updates 04/16:
$BMY $MRK lung data
$CLDX fail -65%
FDA accepts $ALKS NDA
$APRI -35% more trials required
$CLVS -10…
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
@gcbioinv @Kevvy_Kaye Hi, buddies. With today's $MRK and $BMY lung cancer data, I have a feeling that majority of o… https://t.co/D6YpmWReeN
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @jonathanrockoff: $MRK up >2.5%, while $BMY down >8%, on lung-cancer immunotherapy news: https://t.co/PfjUipfQEr. Bernstein's Anderson s…
RT @JacobPlieth: Justin Gainor (Impower-150 discussant) compares KN-189 vs IMP-150. We LOVE cross-trial comparisons, right? $MRK $RHHBY $BM…
RT @JohnCendpts: #2
Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison
$MRK $BMY…
RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
Okay. So $BMY = bad company & great stock and, $MRK = Great company and bad stock. I will never understand how '… https://t.co/RqDzvSlQ68
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @Ogut_Ozgur: Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of approved…
RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
RT @bydavidcrow: Here are my back of envelope comparisons on Merck and Bristol trials (I know, no cross trial comps yadayada, but everyone…
RT @DewDiligence: Slides from $MRK AACR investor webcast:
https://t.co/FuG1GWrg5c
Recommendation #HOLD for $MRK with UB rating - 2.89 out of 5. https://t.co/QmN7roMsl8
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @BursatilBiotech: Gooooooooooooooooooooooooooood Morning, Deareeeeest Biotwitter!
Toooooooooday is D-Day!
1 disease, 3 COs, 3 trials
$B…
@Ogut_Ozgur As BMO put it: "Keytruda + chemo is the new standard of care in all ALK/EGFR negative noon-squamous 1L-… https://t.co/Mc1V0xgUiZ
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @JacobPlieth: Probably the most positive slide for $BMY in CM-227, via M Hellmann #AACR18 $MRK $RHHBY https://t.co/jWPi8Qx3ll
RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
RT @SA_BioTech: $AXON $BIIB $LLY $MRK $VTVT https://t.co/hPZRl4rPeM
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
$LPTX $7.83 +0.34 (4.54%) $MRK $59.24 +0.59 (1.01%) - News Out
https://t.co/aSsM2rGugR
Explore #fundamental numbers and pros and cons for $MRK https://t.co/RMKJb2hbiB
#Merck Cements Lead in #Lungcancer With #BristolMyers Fizzling
#Competition between #pharma is good for #patients… https://t.co/Bn0zKdCJSd
RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
Wondering about risks of $MRK? The 21-day volatility is 7.33% https://t.co/F24Y08wWlG
RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
$MRK high OI range is 55.00 to 57.50 for option expiration 04/20/2018 #maxpain #options https://t.co/biZK1ZVXxB https://t.co/buidhxn7hO
Wondering about risks of $MRK? The 63-day volatility is 12.7% https://t.co/F24Y08wWlG
We calculated 63-day Expected Return of $MRK for you: 0.6% https://t.co/eHMiSmPb0G
I bet the $ONCS partner to b announced soon will be $MRK. Wouldn’t be surprised to ultimately see them combine key… https://t.co/QHVbzOSW1y
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
@JohnTuckerPhD @bradloncar It’s all trial design- $MRK said why beat chemo when you can join it. Blame $BMY for bei… https://t.co/KnLFt1EvFH
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @BioPharmaDive: In KEYNOTE-054, adjuvant treatment with $MRK's Keytruda of Stage 3 melanoma reduced the risk of disease recurrence or de…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
@JSTBiotech I'm not worried about that. Part of the reason for the weakness is great $MRK data for CP + chemo.
Anyo… https://t.co/4TPrzTj43u
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
RT @Merck: Part of our strategy includes collaborating with partners to explore new approaches and therapy combinations that could help peo…
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
RT @Merck: “This year’s @AACR Annual Meeting represents an important milestone for immuno-oncology research and we’re extremely proud to ha…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
$MRK on watch
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @JacobPlieth: $RHHBY Impower-150 PFS results by PD-L1 status, via Mark Socinski (note two different assays...) #AACR18 $MRK $BMY https:/…
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @JacobPlieth: That's clear, right? (Matthew Hellmann, Checkmate-227 redesign.) #AACR18 $BMY $MRK $RHHBY https://t.co/agIwItrdCX
RT @JacobPlieth: Probably the most positive slide for $BMY in CM-227, via M Hellmann #AACR18 $MRK $RHHBY https://t.co/jWPi8Qx3ll
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
RT @Merck: Part of our strategy includes collaborating with partners to explore new approaches and therapy combinations that could help peo…
RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
Research Analysts Offer Predictions for Merck & Co.’s Q1 2018 Earnings $MRK https://t.co/tn0qmtsdMN
Research Analysts Offer Predictions for Merck & Co.’s Q1 2018 Earnings $MRK https://t.co/N254C48l3y
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @bydavidcrow: Here are my back of envelope comparisons on Merck and Bristol trials (I know, no cross trial comps yadayada, but everyone…
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
$ALKS $BMY $JNJ $MRK https://t.co/8u9uVNGt0n
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
RT @JacobPlieth: Take that, $BMY. Keytruda's knockout blow in 1st-line NSCLC? $MRK #AACR18 https://t.co/D39w38xTqr
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @endpts: Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison https://t.co/zhvTj…
RT @kjilly: #IO combos inch forward in #pharma's #lungcancer quest #biotech #biopharma #biotechnology #NSCLC #AACR18 #immunooncology #Opdiv…
Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison… https://t.co/wlpUREtYNC
Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update https://t.co/hg3CNxxgeF #investing… https://t.co/iAX3jLzftz
RT @JohnCendpts: #AACR18 brawl. $MRK data: Keytruda/chemo reduces risk of death by 51% -- in high PD-L1 58%. HR of 0.49.
https://t.co/4Kpcx…
RT @SeekingAlpha: $ALKS $BMY $JNJ $MRK https://t.co/8u9uVNGt0n
The past week $BMY had been going DOWN while $MRK had been creeping UP. Something tells me the cancer trial informa… https://t.co/G6rioVSzZW
RT @JacobPlieth: $MRK crushes $BMY (and perhaps $RHHBY too). My take on today's #AACR18 showdown, via @EPVantage https://t.co/bgoFcCRa1g
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
Jefferies Group Reiterates $56.00 Price Target for Merck & Co. $MRK https://t.co/NU4cNLyYJE
RT @zbiotech: spectacular NEJM data $MRK 189 OS KM and subgroups https://t.co/8cQz63yFw3
While everyone's chewing on the data and the Merck vs BMS / pembro vs nivo discussion, let's not forget about the i… https://t.co/wXneEoRnvL
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
@jq1234t @bradloncar A PD-L1+/- analysis of CM-227 be when $MRK Keytruda+chemo can be used in all-comers, and Keytr… https://t.co/9U1zzd4wea
A loophole for $bmy in 1st line nsclc might be the relatively high number of patients with symptomatic brainmets. D… https://t.co/cnGoFDhjfJ
RT @Ogut_Ozgur: Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of approved…
RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
RT @Ogut_Ozgur: Today’s $mrk result in NSCLC just affirms to me that it is basically unethical to withhold clinical trial data of approved…
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @DewDiligence: Slides from $MRK AACR investor webcast:
https://t.co/FuG1GWrg5c
Morgan Stanley Upgrades Merck $MRK to Overweight https://t.co/Cihq17yxzY
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
@jq1234t @bradloncar A PD-L1+/- analysis of CM-227 when $MRK Keytruda+chemo can be used in all-comers, and Keytruda… https://t.co/X4bqi6c38C
RT @OpenOutcrier: $MRK (+0.5% pre) Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percen…
RT @OpenOutcrier: $MRK (+0.5% pre) Why Merck Is Betting Big on One Cancer Drug - WSJ
https://t.co/5vMoVT25L7
Lung Cancer Patients Live Longer With Immune Therapy https://t.co/okEy7qE06W $BMY $MRK
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
RT @AndyBiotech: #AACR18 first-line NSCLC I/O showdown in NEJM
$MRK Keynote-189
https://t.co/rkqySZYSLo
$BMY Checkmate-227 TMB
https://t…
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
#Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC $SSO $BUD $SHPG
RT @wboscoho: $BMY $MRK
RT
Lung Cancer Patients Live Longer With Immune Therapy https://t.co/2KjXaTWSqH
$MRK upgraded to Overweight at Morgan Stanley. PT $68
$BMY $MRK
RT
Lung Cancer Patients Live Longer With Immune Therapy https://t.co/2KjXaTWSqH
RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
RT @drug_czar: With a week left to go, here's a preview of the Immunotherapy-combo showdown at #AACR18 where Keytruda, Opdivo, and Tecentri…
Merck & Co.’s $MRK “Buy” Rating Reaffirmed at BMO Capital Markets https://t.co/q0k1NytbBk
RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
$MRK upgraded to Overweight at Morgan Stanley. PT $68
Baml $MRK emerging as clear IO leader in lung cancer
raising Keytruda sales forecasts based on strength of Phase 3… https://t.co/FYpKjLZ3PF
RT @drug_czar: Head still spinning from the IO showdown at #AACR18? To keep track of the data, I have a comparison of the PFS and OS hazard…
RT @BobbyLandman121: Keynote189 vs IMpower150 comparison $MRK $AZN #AACR18 https://t.co/1AdTLNHLDj
‘Keytruda is King’ in lung cancer, putting BMS and next-gen in the shade https://t.co/OILpNPRbjN #AACR18 $MRK $NKTR $BMS
RT @wboscoho: $BMY $MRK
RT
Lung Cancer Patients Live Longer With Immune Therapy https://t.co/2KjXaTWSqH
RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
RT @ACInvestorBlog: Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
RT @ACInvestorBlog: Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
https://t.co/2WASIf0beT
$JNJ $PFE $MRK #earnings #pharmastock #Cancer #stocknews #Markets
RT @bydavidcrow: Here are my back of envelope comparisons on Merck and Bristol trials (I know, no cross trial comps yadayada, but everyone…
RT @bydavidcrow: Credit Suisse calls it for Merck $MRK $BMY https://t.co/mIhbsL4ePj
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
RT @tgtxdough: LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK #AACR18 https…
RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
RT @Merck: Our commitment to patients living with #lungcancer has never been stronger. Together we’ll continue to look for new ways to figh…
RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
RT @JacobPlieth: OS and PFS curves in $MRK Keynote-189 by PD-L1 expression, via Leena Gandhi #AACR18 $BMY $RHHBY https://t.co/WGvS4jpAdd
Steve Scala publishes pharma sector investment takeaways from #AACR18 $MRK $BMY $AZN $RHHBY
Further $LPTX commentary from Laden - treating physician called one patient's response "a miracle" and Merck $MRK "… https://t.co/yK5AqFdeCp
RT @Merck: Looking forward to sharing our latest #cancer research development updates during our #AACR18 investor briefing! $MRK https://t.…
RT @bydavidcrow: Merck’s stunning lung cancer trial makes FT front page. $MRK $BMY #AACR18 https://t.co/JnXMVqNZmX
Merck & Co. $MRK Upgraded to “Buy” by Morgan Stanley https://t.co/RFWxaLR3B6
RT @tgtxdough: LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK #AACR18 https…
RT @tgtxdough: LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK #AACR18 https…
LADEN $LPTX 2nd note LPTX Stock Drop After DKN-01+Keytruda AACR2018 Data Unwarranted; Reiterate Buy PT 18 $MRK… https://t.co/Boe63UmTcn
Merck & Co. $MRK Upgraded to “Buy” by Morgan Stanley https://t.co/G9bAXnHVrw
PM Top % Gainers: $CNET $DPW $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD $HMY $BUD $AMD
Gainers Premarket $ROKU $NFLX $TQQQ $TWTR $DGAX $UPRO $QLD $SPXL $NOK $UNH $MRK $TNA $AMD $BUD $SHPG $SSO
https://t.co/jpobP3U3HN
#TRADING US PM Gapers $NFLX $UNH $ROKU $SHPG $BUD $MRK $WPP $TWTR $RDS.A $PHG $YNDX $BAC $HMNY $AMD $NOK $HMY $BABA… https://t.co/dp6OhUSF3P
RT @Super1NYC: #Premarket Top % Gainers: $CNET 30%, $DPW 15%, $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD…
Upgrades $CCE $AXTI $ABB $PHG $TWTR $NTAP $NWL $MRK $DIS $KO $TRMB $DG
$KTOV Highlights of TyrNovo's NT-219 recent promising results from Kitov last presentation #AACR18 $MRK $LLY https://t.co/9Yi3pa6CnV
JPM currently assumes 45% mkt share for $MRK which could proove conservative, each additional 10% share bumps peak… https://t.co/qYCk3PTo4X
GS - $BMY data was solid but significantly overshadowed by $MRK
$NKTR Wainwright attributes selloff to belief that $MRK has first mover advantage in non-squamous NSCLC. Believes… https://t.co/IcqXdSpzDN
$MRK Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine https://t.co/XUj8XMe0Kt
$MRK:
Merck Announces First Phase Three Studies for PCV-15 (V114) Its …:
https://t.co/cPkzYUs8hm
$MRK Pretty sure Merck was buying back their own shares last quarter. Merck going to $70 this year for sure. https://t.co/REtHfcs3yY
$MRK Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine https://t.co/QJxt6U62z3
RT @Super1NYC: #Premarket Top % Gainers: $CNET 30%, $DPW 15%, $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD…
RT @Super1NYC: #Premarket Top % Gainers: $ASFI 8%, $ROKU $NFLX $YANG $HMNY $TWTR $TQQQ $ZUO $DGAZ $YNDX $TEO $NOK $PHG $HMY $MRK $IQ $PSEC…
Given the examples in the article, $MRK $RHHBY $PFE $GILD $KITE $SNY $CELG and DOZEN more from $XBI $IBB should be… https://t.co/cB5l1rNwld
$MRK: GapUP 1.25[+2.1%,fill:27%], PrvCl:58.65, PrvHi:59.25, 1NewHi, PDayGp+, 47:6Accel+, allTFs+, bigFlt:2.7B, 1MoHi+, p$vol:3.85M
RT @JSTBiotech: Further $LPTX commentary from Laden - treating physician called one patient's response "a miracle" and Merck $MRK "encourag…
$NVCN Press Release from Feb 2018, March regained compliance with TSX, April Boston SCIENTIFIC, Warrants, May Earni… https://t.co/1Zrt1sMbAP
$MRK Well done. Crossing SMA200.
Merck & Co. $MRK Raised to “Buy” at Morgan Stanley https://t.co/OfgzOYMsAV #stocks
RT @tgtxdough: $MRK #KEYTRUDA Currently have 759 trials listed on https://t.co/0g3i1CrgVf
o Studying >400 combos
o 12 breakthrough therapie…
MS $MRK upgrading MRK from EW to OW raising PT from $63 to $68. Keytruda showed better-than-expected KN-189 lung re… https://t.co/35t7vYVxVv
GS - $MRK emerged the clear winner post AACR investor presentation, incremental 10% gain in mkt share (at minimum)… https://t.co/6EeetYjODR
RT @tgtxdough: $MRK #KEYTRUDA Currently have 759 trials listed on https://t.co/0g3i1CrgVf
o Studying >400 combos
o 12 breakthrough therapie…
$MRK #KEYTRUDA Currently have 759 trials listed on https://t.co/0g3i1CrgVf
o Studying >400 combos
o 12 breakthrough… https://t.co/NGpGOuTWCi
#Premarket Top % Gainers: $CNET 30%, $DPW 15%, $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL… https://t.co/9Hmd2x5bmc
Merck & Co.’s $MRK “Buy” Rating Reaffirmed at BMO Capital Markets https://t.co/ow2AF2hnaE
RT @BioStocks: $MRK upgraded to Overweight at Morgan Stanley. PT $68
Intensity is the price of excellence
$MYMX The Best Stock Investment For 2018
HIV Vaccine 100% Effective
Now At… https://t.co/XRwNiO3ou2
RT @dixielee1969: PM Top % Gainers: $CNET $DPW $ROKU $ARQL $NFLX $AVXL $TQQQ $IQ $DBX $TWTR $UNH $NOK $HMNY $SPXL $MRK $RAD $HMY $BUD $AMD
Target Raised https://t.co/2Wn5XwkMO6 $ICFI $INTC $JBHT $LULU $MA $MB $MNRO $MRK $MTB $NFLX $NUE $RHT $SCHW $STLD $THG $TPR $ULTI $VIAB